Analysis Tools
mortality/aging
|
• mean age of death is about 314 days
|
immune system
|
• increased apoptosis of B cells from young homozygotes is seen in culture without activating stimuli; however, B cells from lymphomas remain viable in culture for longer periods of time compared to wild-type cells
|
|
• antigen-stimulated B cell proliferation is increased about 2-fold compared to wild-type mice and the number of B cells in S and G2/M phase is increased to 47% compared to 24% of wild-type B cells
|
|
• around 10 months of age, a profound enlargement of the spleen is seen
|
|
• around 10 months of age, a 5-12 fold increase in spleen weight is seen
|
|
• in young (6 weeks-3months) mutants, the percentage of B cells in the spleen is increased with a 7-10 fold increase in the B220+IgM+IgDlow cell population and a slight increase in the B220+IgM+ cell population is seen in the bone marrow
|
|
• in young (6 weeks-3months) mutants, the percentage of T cells in the spleen is decreased; however T cell development in the thymus is normal and the ratio of CD4 and CD8 cells is similar to wild-type
|
|
• around 10 months of age profound enlargement of the lymph nodes is seen
|
neoplasm
|
• B cell derived lymphomas with diffuse infiltration in the spleen and lymph nodes, varying degrees of infiltration into the lung, kidney, and intestine, and a 'starry sky' appearance characteristic of Burkitt's lymphoma are seen
|
hematopoietic system
|
• increased apoptosis of B cells from young homozygotes is seen in culture without activating stimuli; however, B cells from lymphomas remain viable in culture for longer periods of time compared to wild-type cells
|
|
• antigen-stimulated B cell proliferation is increased about 2-fold compared to wild-type mice and the number of B cells in S and G2/M phase is increased to 47% compared to 24% of wild-type B cells
|
|
• around 10 months of age, a profound enlargement of the spleen is seen
|
|
• around 10 months of age, a 5-12 fold increase in spleen weight is seen
|
|
• in young (6 weeks-3months) mutants, the percentage of B cells in the spleen is increased with a 7-10 fold increase in the B220+IgM+IgDlow cell population and a slight increase in the B220+IgM+ cell population is seen in the bone marrow
|
|
• in young (6 weeks-3months) mutants, the percentage of T cells in the spleen is decreased; however T cell development in the thymus is normal and the ratio of CD4 and CD8 cells is similar to wild-type
|
cellular
|
• increased apoptosis of B cells from young homozygotes is seen in culture without activating stimuli; however, B cells from lymphomas remain viable in culture for longer periods of time compared to wild-type cells
|
|
• antigen-stimulated B cell proliferation is increased about 2-fold compared to wild-type mice and the number of B cells in S and G2/M phase is increased to 47% compared to 24% of wild-type B cells
|
growth/size/body
|
• around 10 months of age, a profound enlargement of the spleen is seen
|
|
• around 10 months of age, a 5-12 fold increase in spleen weight is seen
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| Burkitt lymphoma | DOID:8584 |
OMIM:113970 |
J:97900 | |
